Stay updated with breaking news from Trial Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases
Search jobs 24-Dec-2020 INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the publication of peer-reviewed Phase 1 clinical data from the first cohort of 40 participants for its COVID-19 DNA vaccine candidate, INO-4800, in EClinica...
Hummingbird, Tempus collaborate to harness AI-driven precision medicine One percent of all solid tumors harbor NRG1 fusions, a rare genetic mutation that drives malignancies. Singapore biotech company Hummingbird Bioscience has announced a collaboration with technology company Tempus to harness AI and big data in support of a biomarker-driven clinical trial for Hummingbird’s anti-HER3 antibody, HMBD-001, including those that harbor neuregulin 1 (NRG1) fusions. NRG1 fusions are a rare genetic mutation that are increasingly recognized as a driver of multiple tumor malignancies, and an actiona...
Published: Dec 15, 2020 PLYMOUTH MEETING, Pa., Dec. 15, 2020 /PRNewswire/ -- Inovio (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the company and a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University received a $37.6 million grant from the Defense Advanced Research Projects Agency (DARPA) (DARPA), a research and development agency of the U.S. Department of Defense (DoD) and the Joint Progr...
Share this article Share this article SINGAPORE, Dec. 14, 2020 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, today announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to drive the development of Hummingbird's lead clinical program, HMBD-001, as it advances into clinical trials in HER3-driven cancers, including those that harbor neuregulin 1 (NRG1) fusions. As part of the collaboration, Hummingbird will be leveraging Tempus' AI-enabled pl...